Cigna Group's performance and all-time high raise questions about selling its stock, but I still prefer to hold despite high valuation. Read more on CI stock here.

In the latest market close, Cigna (CI) reached $292.07, with a +0.54% movement compared to the previous day. The stock outpaced the S&P 500's daily gain of 0.45%.

During the last three months, 8 analysts shared their evaluations of Cigna (NYSE:CI), revealing diverse outlooks from bullish to bearish.The table below provides a concise overview of recent ...

Cigna stock gets a Buy rating today. Strengths: dividends, valuation, revenue growth, net income & EPS, share price vs. moving average, capital & liquidity. Offsetting factors: price performance ...

The subdued stock price reaction suggests that The Cigna Group's (NYSE:CI) strong earnings didn't offer any surprises. Our analysis suggests that investors might be missing some promising details ...

Get the latest news on Cigna Group stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on CI performance ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $300.0 and $340.0 for Cigna Group, spanning the last three months ...

The Cigna Group (CI), headquartered in Bloomfield, Connecticut, provides insurance and related products and services. Valued at $84.6 billion by market cap, the company offers life, accident ...

Cigna is up 1.3% since the beginning of the year, but at $278 per share, it is still trading 24.2% below its 52-week high of $366.85 from September 2024.

Cigna stock (NYSE: CI), a health insurance and pharmacy services management company, has seen a 9% rise in a month, significantly outperforming the broader S&P500 index, which fell 5%.

Analyst Justin Lake of Wolfe Research reiterated a Buy rating on Cigna (CI – Research Report), with a price target of $323.00. Justin Lake gave his rating of Cigna’s stock based on a number of ...

Cigna's stock leads selloff among drug middlemen on breakup fears - but this analyst says it's not a real risk Provided by Dow Jones Dec 12, 2024 12:22pm By Ciara Linnane ...